Human Respiratory Syncytial Virus Drugs Dominated by Synagis, the only Approved Drug in the Market: Technavio Technavio publishes a new market research report on the global human respiratory syncytial ...

A new study from researchers at Columbia University Vagelos College of Physicians and Surgeons shows that a drug given to some pregnant women to prevent severe respiratory ailments in preterm newborns ...

In early April, Pfizer announced a $525 million acquisition of ReViral’s novel therapy for respiratory syncytial virus (RSV). Since then, RSV therapies have garnered renewed global attention. However, ...

GSK’s respiratory drug lineup spans a newly approved product for chronic obstructive pulmonary disease as well as therapeutic candidates in various stages of clinical development for treating this ...

More than one-quarter of $1 billion could flow to a Swiss drug maker under a licensing deal concerning investigational drugs for respiratory infections and herpes. “Today’s announcement builds on ...

DelveInsight's,“ Respiratory Syncytial Virus Pipeline Insight 2025 ” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Respiratory Syncytial Virus (RSV) pipeline ...

Muscle relaxants are a necessary part of anesthesia during certain major operations. Studies have, however, hinted at respiratory risks connected with these drugs. A major new study has confirmed the ...

GlaxoSmithKline has terminated (PDF) 11 projects over the past 12 months. The respiratory franchise bore the brunt of the cuts at a time when some GSK staff were questioning the wisdom of investing in ...

LONDON--(BUSINESS WIRE)--The global bronchiectasis drugs market is expected to post a CAGR close to 5% during the period 2019-2023, according to the latest market research report by Technavio. The ...

The study of the respiratory system microbiome is a burgeoning field that has recently garnered significant attention.